within Pharmacolibrary.Drugs.N_NervousSystem.N05B_Anxiolytics.N05BA11_Prazepam;
model Prazepam 
   extends Pharmacolibrary.Drugs.ATC.N.N05BA11;

  annotation(Documentation(
    info ="<html><body><p>Prazepam is a benzodiazepine derivative drug used primarily as an anxiolytic for the short-term management of anxiety disorders. It is a prodrug for desmethyldiazepam (nordiazepam), which is its main active metabolite. Due to concerns over dependence and newer alternatives, use of prazepam has declined and it is not widely approved or marketed in many countries today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult volunteers after single oral administration.</p><h4>References</h4><ol><li><p>Kölle, EU (1981). [Pharmacokinetics of oral prazepam]. <i>Fortschritte der Medizin</i> 99(22) 874–879. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/6790396/&quot;>https://pubmed.ncbi.nlm.nih.gov/6790396</a></p></li><li><p>Jacqmin, P, &amp; Ansseau, M (1988). Comparison of sublingual and oral prazepam in normal subjects. II. Pharmacokinetic and pharmacodynamic data. <i>Neuropsychobiology</i> 19(4) 186–191. DOI:<a href=&quot;https://doi.org/10.1159/000118458&quot;>10.1159/000118458</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2854609/&quot;>https://pubmed.ncbi.nlm.nih.gov/2854609</a></p></li><li><p>Allen, MD, et al., &amp; Shader, RI (1980). Desmethyldiazepam kinetics in the elderly after oral prazepam. <i>Clinical pharmacology and therapeutics</i> 28(2) 196–202. DOI:<a href=&quot;https://doi.org/10.1038/clpt.1980.150&quot;>10.1038/clpt.1980.150</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/6772370/&quot;>https://pubmed.ncbi.nlm.nih.gov/6772370</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end Prazepam;
